Cerus (CERS) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Cerus Corporation Reports First Quarter 2016 Results
May 3, 2016 4:01 PM EDTCONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ: CERS) today announced financial results for the first quarter ended March 31, 2016.
Recent company highlights include:
Entered into long-term INTERCEPT platelet and plasma supply agreement with the American Red Cross, the largest U.S. supplier of blood components. Entered into framework agreement with Blood Centers of America (BCA) as its pathogen reduction technology supply partner. Fifteen BCA members are now under contract for use of the INTERCEPT Blood System. Received... MoreCerus Announces that the Walter Reed National Military Medical Center Has Entered Into Routine Use of the INTERCEPT Blood System
May 3, 2016 8:30 AM EDTCONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ: CERS), a biomedical products company focused in the field of blood transfusion safety, announced today that the Walter Reed National Military Medical Center (Walter Reed), a component of the Armed Services Blood Program, has begun routine use of the INTERCEPT Blood System for apheresis platelets. Walter Reed transfuses approximately 1,000 apheresis platelet units annually.
Walter Reed now joins the growing list of centers in routine production of platelets treated using the INTERCEPT Blood System, commented William Obi Greenman, Cerus president and chief executive officer. Similar to the... More
